SMT C1100

1 stories · following the connections

Business

Summit Reports Positive Interim Data From Ongoing Phase 1 Clinical Trial Testing a New Formulation of SMT C1100 in Patients With DMD

By Nasdaq OMXMar 30, 2016, 11:00 AM UTC